Is NADH Effective in the Treatment of Parkinson’s Disease?

@article{Swerdlow1998IsNE,
  title={Is NADH Effective in the Treatment of Parkinson’s Disease?},
  author={Russell H Swerdlow},
  journal={Drugs \& Aging},
  year={1998},
  volume={13},
  pages={263-268}
}
  • R. Swerdlow
  • Published 1 October 1998
  • Biology
  • Drugs & Aging
Most Parkinson’s disease (PD) treatments palliate symptoms by increasing nigrostriatal dopaminergic tone. A unique strategy for accomplishing this pharmacological end-point proposes using reduced nicotinamide adenine dinucleotide (NADH) to boost endogenous dopamine production, since NADH indirectly supplies reducing equivalents to the rate-limiting, tyrosine hydroxylase-catalysed step of dopamine synthesis. Support for using NADH in PD treatment includes claims that NADH stimulates tyrosine… 

A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

TLDR
A logical and efficient strategy for PD treatment is based on correcting or bypassing the enzyme deficiency by the treatment with L-DOPA, DA agonists, inhibitors of DA metabolism or brain grafts with cells expressing a high level of TH.

Effects of NADH on dopamine release in rat striatum

TLDR
Results indicate that NADH can increase DA release from striatal slices, although the authors are as yet unable to detect this effect in vivo.

No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia

TLDR
It is concluded that NADH is unlikely to achieve cognitive improvements in an extent reported earlier, and theoretical arguments against an effectiveness of this compound in dementia disorders are presented.

PGC-1α, Sirtuins and PARPs in Huntington’s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All

TLDR
The potential synergistic effect of increasing NAD+ combined with PARPs inhibitors, as a clinical therapeutic option not only in HD, but other neurodegenerative conditions is discussed.

Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem.

  • R. Swerdlow
  • Biology, Medicine
    Antioxidants & redox signaling
  • 2007
TLDR
The role of mitochondrial function and dysfunction in aging and neurodegenerative diseases is discussed, potential treatment strategies are focused on, and increasing ETC capacity, increasing oxidative phosphorylation, or decreasing mitochondrial ROS seems increasingly feasible.

Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH.

TLDR
Intraperitoneal injection of Nam, NAD+ and NADH produced significant increases in urinary excretion of Nam and its metabolites, suggesting that NADH in digestive organs has been decomposed to a compound(s) that cannot yield Nam.

Evaluation of clinical relationship of serum niacin and dopamine levels in patients with fibromyalgia syndrome

TLDR
Serum niacin and DA levels decrease in FMS patients in relation to the tender point numbers, and it can be suggested that the levels of these two markers can be considered additional tools in the diagnosis of FMS.

Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice.

NAD+ and NADH in brain functions, brain diseases and brain aging.

  • W. Ying
  • Biology
    Frontiers in bioscience : a journal and virtual library
  • 2007
TLDR
It is proposed that NAD+ and NADH are fundamental mediators of brain functions, brain senescence and multiple brain diseases, together with ATP and Ca2+, constitute a Central Regulatory Network of life.

2‐Deoxy‐D‐Glucose Prevents and Nicotinamide Potentiates 3,4‐Methylenedioxymethamphetamine‐Induced Serotonin Neurotoxicity

TLDR
The results suggest that an altered energy metabolism is not the main cause of the neurotoxic effects induced by MDMA, and that the long‐term 5‐HT deficitsinduced by MDMA were potentiated by nicotinamide in all the brain regions examined.

References

SHOWING 1-10 OF 29 REFERENCES

Treatment of Parkinson's disease with NADH

TLDR
The results indicate that no great changes are obtained after short‐term treatment of parkinsonian patients with NADH, neither clinically nor biochemically.

Mitochondrial Complex I Deficiency in Parkinson's Disease

TLDR
Results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease, which adds further support to the proposition that Parkinson’s disease may be due to an environmental toxin with action(s) similar to those of MPTP.

Stimulation of endogenous L‐dopa biosynthesis — a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)

Abstract– The coenzyme nicotinamide adenine dinucleotide (NADH) has been used as a novel medication in 161 Parkinson patients in an open label trial. In all but 18 patients (11.2%) an improvement in

Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers

TLDR
Iron infusion into the SN can cause degenerative changes within the SN and that these changes can be restricted to the SNc region when low amounts of iron are infused, which further support the hypothesis that iron‐induced degeneration may contribute to the pathogenesis of PD.

The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients

SummaryThe coenzyme nicotinamide adenine dinucleotide (NADH) has been used in an open label trial as novel medication in 34 patients with Parkinson's disease, using an intravenous administration

Abnormalities of the electron transport chain in idiopathic parkinson's disease

TLDR
It is hypothesized that the complex I abnormality may have an etiological role in the pathogenesis of Parkinson's disease and that this defect may be derived via the mitochondrial genome.

Oxidative stress and the pathogenesis of Parkinson's disease

TLDR
Selegiline may act through a mechanism unrelated to MAO-B to increase neurotrophic factor activity and upregulate molecules such as glutathione, SOD, catalase, and BCL-2 protein, which protect against oxidant stress and apoptosis.

Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution.

TLDR
Intravenously applied iron in the form of a ferri-ferro-complex exhibits a considerable benefit for all patients treated so far, and they regained a remarkable mobility.

CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.

TLDR
TH activity in the caudate nucleus of individuals with both hepatic and diabetic coma were within normal ranges, suggesting a sufficient energy supply of the brain during such metabolic catastrophes, while reduced brain TH activity in patients with hepatic coma who died of acute gastrointestinal bleeding is probably due to severe final cerebral ischemia.